世卫组织预先认定诺华公司的首次疟疾治疗方法适用于体重在2至5公斤之间的婴儿. WHO prequalifies Novartis' first malaria treatment for infants weighing 2 to 5 kg.

诺华公司已获得世界卫生组织的Coartem Baby预资格,这是首款针对体重在2至5公斤之间的婴儿治疗疟疾的药物. Novartis has received World Health Organization prequalification for Coartem Baby, the first malaria treatment for infants weighing 2 to 5 kilograms. 这种与"抗疟疾药物公司"的合作为以前被迫使用成人剂量的婴儿提供了安全,具体的选择,降低毒性风险. This collaboration with Medicines for Malaria Venture provides a safe, specific option for infants previously forced to use adult dosages, reducing toxicity risks. 在疟疾流行地区, 治疗正在以非营利性方式提供, 最初在加纳推出. The therapy is being made available on a not-for-profit basis in malaria-endemic regions, with initial rollout in Ghana.